摘要
目的基于数据挖掘和网络药理学方法,研究2019新型冠状病毒肺炎官方公布预防方药组方规律和作用机制,为新冠肺炎的防治提供指导。方法采用数据挖掘和关联规则分析方法,研究新冠肺炎预防方药组方规律;进一步采用网络药理学方法,通过KEGG通路和基因本体富集分析,研究高频核心药物的生物信号通路,阐明其作用机制。结果筛选官方公布的新冠肺炎预防方剂和中成药63个,发现14味高频中药,进一步关联分析得到14个高频药对和15个高频药组。在此基础上,采用网络药理学方法,研究高频核心药组作用机制,发现"防风、白术和黄芪"主要通过干预氨基酸代谢、嘌呤代谢等基础代谢途径发挥预防作用,而"藿香和苍术"除基础代谢外,还通过参与炎症相关反应发挥预防治疗作用。结论新冠肺炎预防方药的核心药组"防风、白术和黄芪"和"藿香和苍术"分别通过基础代谢和炎症相关通路发挥预防疗效,为主动健康指导方针下的"未病先防"提供参考。
Objective Based on data mining and network pharmacology,the objective of this research is to explore the prescription rules and mechanism of traditional Chinese medicine(TCM)prevention for 2019 novel coronavirus pneumonia(COVID-19).Methods Data mining and association rules were used to investigate the rules of officially announced TCM prevention prescription.Furthermore,KEGG pathway and Gene Ontology analysis were performed by BATMAN-TCM to investigate the potential signaling pathways of core drugs for novel coronavirus pneumonia prevention.Results Based on the 63 formulas and Chinese patent medicine included in this research,14 high-frequency Chinese Materia Medica were counted.Moreover,14 high-frequency medicine pair and 15 high-frequency medicine group were found out by association rules analysis.Interestedly,“Fang Feng,Bai Zhu and Huang Qi”and“Huo Xiang and Cang Zhu”were the critical high-frequency medicine group.The former plays a preventive role mainly by interfering with basic metabolic pathways such as amino acid metabolism and purine metabolism,while the latter by participating in inflammation-related reactions in addition to basic metabolism.Conclusion The critical medicine groups of novel coronary pneumonia prevention formulae are“Fang Feng,Bai Zhu and Huang Qi”and“Huo Xiang and Cang Zhu”,which exert preventive effects through basal metabolism and inflammation-related pathways,respectively.This provides a guideline for“prevention before disease”.
作者
马丽娟
暴正瀚
雷乐庭
王逸飞
朱振宇
王济
王琦
乔延江
郑燕飞
吴志生
Ma Lijuan;Bao Zhenghan;Lei Leting;Wang Yifei;Zhu Zhenyu;Wang Ji;Wang Qi;Qiao Yanjiang;Zheng Yanfei;Wu Zhisheng(School of Chinese Materia Medica,Beijing University of Chinese Medicine,Beijing 102488,China;Fangshan Hospital,Beijing University of Chinese Medicine,Beijing 102400,China;School of Traditional Chinese Medicine,Beijing university of Chinese Medicine,Beijing 100029,China)
出处
《世界科学技术-中医药现代化》
CSCD
北大核心
2020年第3期566-572,共7页
Modernization of Traditional Chinese Medicine and Materia Medica-World Science and Technology
基金
国家科学技术部国家重大新药创制项目(2018ZX090205):中药丸剂智能制造关键技术与应用研究,负责人:吴志生
国家科学技术部国家重点研发计划项目(2018YFC1706901):中药固体制剂(片剂)的剂型改进设计与优化关键技术研究,负责人:吴志生
北京中医药大学创新团队项目(2019-JYB-TD-011):中药智能制造与全程质量控制,负责人:吴志生
中华中医药学会青年托举工程(QNRC2A03):中药先进制药控制技术,负责人:吴志生。
关键词
数据挖掘
网络药理学
新型冠状病毒肺炎
中医药
预防方药
Data mining
network pharmacology
novel coronavirus pneumonia
traditional Chinese medicine
preventive recipes
